The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria

References

• Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–679. PMID: 21896369. doi: 10.1016/j.euroneuro.2011.07.018.
   PubMed Web of Science ®Google Scholar
• Goodwin RD, Dierker LC, Wu M, et al. Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap. Am J Prev Med. 2022;63(5):726–733. doi: 10.1016/j.amepre.2022.05.014.
   PubMed Web of Science ®Google Scholar
• Steffen A, Holstiege J, Akmatov MK, et al. Zeitliche Trends in der Diagnoseprävalenz depressiver Störungen: eine Analyse auf Basis bundesweiter vertragsärztlicher Abrechnungsdaten der Jahre 2009 bis 2017 [Temporal trends in the diagnosis prevalence of depressive disorders: an analysis based on nationwide panel physician billing data from 2009 to 2017]. Berlin (Germany): Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland (Zi); 2019. Versorgungsatlas.de. 2019;19/05. doi: 10.20364/VA-19.05.German.
   Google Scholar
• Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247. doi: 10.1186/s12888-019-2222-4.
   PubMed Web of Science ®Google Scholar
• Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US Commercial Claims Database. J Clin Psychiatry. 2018;79(2):24–32. doi: 10.4088/JCP.17m11725.
   Web of Science ®Google Scholar
• Chow W, Doane MJ, Sheehan J, et al. Economic burden among patients with major depressive disorder: an analysis of healthcare resource use, work productivity, and direct and indirect costs by depression severity. Am J Manag Care. 2019;24(2):1–3.
   Google Scholar
• European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment of depression. London (UK): EMA; 30 May 2013. EMA/CHMP/185423/2010 Rev 2.
   Google Scholar
• Bschor T, Bauer M, Adli M. Chronic and treatment resistant depression: diagnosis and stepwise therapy. Dtsch Arztebl Int. 2014;111(45):766–775; quiz 775. doi: 10.3238/arztebl.2014.0766.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi: 10.1176/ajp.2006.163.11.1905.
   PubMed Web of Science ®Google Scholar
• Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070. doi: 10.4088/jcp.v68n0713.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. Global health estimates: leading causes of DALYs. Global Health Estimates 2019 summary tables. Geneva (Switzerland): WHO; [cited 2023 Jun 12]. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys
   Google Scholar
• Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–162. doi: 10.4088/JCP.14m09298.
   PubMed Web of Science ®Google Scholar
• Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35(4):512–522. doi: 10.1016/j.clinthera.2012.09.001.
   PubMed Web of Science ®Google Scholar
• Arnaud A, Suthoff E, Tavares RM, et al. The increasing economic burden with additional steps of pharmacotherapy in major depressive disorder. Pharmacoeconomics. 2021;39(6):691–706. doi: 10.1007/s40273-021-01021-w.
   PubMed Web of Science ®Google Scholar
• Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. doi: 10.4088/JCP.20m13699.
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Hornberger JC, Altar CA, et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 2014;65(8):977–987. doi: 10.1176/appi.ps.201300059.
   PubMed Web of Science ®Google Scholar
• Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234. doi: 10.2147/NDT.S198774.
   PubMed Web of Science ®Google Scholar
• Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327–337. doi: 10.3350/cmh.2014.20.4.327.
   PubMedGoogle Scholar
• Soguel N, van Griethuysen P. Cost of illness and contingent valuation: controlling for the motivations of expressed preferences in an attempt to avoid double counting. Économie publique/Public economics [En ligne], 12 | 2003/1, mis en ligne le 03 janvier 2006, consulté le 28 août 2023. Available from: http://journals.openedition.org/economiepublique/400 doi: 10.4000/economiepublique.400.
   Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409–418. doi: 10.1111/j.1524-4733.2008.00489.x.
   PubMed Web of Science ®Google Scholar
• Traunfellner M. PMH20 healthcare utilization in patients with treatment-resistant depression (TRD) in Austria. Value Health. 2020;23:S587–S588. doi: 10.1016/j.jval.2020.08.1098.
   Google Scholar
• Page M, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. doi: 10.1016/j.ijsu.2021.105906.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
   PubMed Web of Science ®Google Scholar
• Špacírová Z, Epstein D, García-Mochón L, et al. A general framework for classifying costing methods for economic evaluation of health care. Eur J Health Econ. 2020;21(4):529–542. Erratum in: Eur J Health Econ. 2021;22(5):847. doi: 10.1007/s10198-019-01157-9.
   PubMed Web of Science ®Google Scholar
• Melchior H, Schulz H, Härter M. Faktencheck Gesundheit – Regionale Unterschiede in der Diagnostik und Behandlung von Depressionen [Health fact check. Regional differences in the diagnosis and treatment of depression]. Gütersloh (Germany): Bertelsmann Stiftung; 2014. German.
   Google Scholar
• Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57–66. doi: 10.3949/ccjm.75.1.57.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(Suppl 8):17–25.
   PubMed Web of Science ®Google Scholar
• Bergfeld IO, Mantione M, Figee M, et al. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362–367. doi: 10.1016/j.jad.2018.04.016.
   PubMed Web of Science ®Google Scholar
• Apoverlag – Warenverzeichnis online [Internet]. Vienna (Austria): Österreichische Apotheker-Verlagsgesellschaft m.b.H. [cited 2021 Jul 12]. Available from: https://warenverzeichnis.apoverlag.at/
   Google Scholar
• Konstantinidis A, Papageorgiou K, Grohmann R, et al. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol. 2012;15(4):449–457. doi: 10.1017/S1461145711000745.
   PubMed Web of Science ®Google Scholar
• IQVIA DPMÖ – Sonderstudie 2019 [Excel file]. Vienna (Austria): IQVIA Austria. 2020 [cited 15.07.2021].
   Google Scholar
• Kasper S, Erfurth A, Sachs G, et al. Therapieresistente Depression: diagnose und Behandlung, Konsensus-Statement [Treatment-resistant depression: diagnosis and treatment, consensus statement]. Sonderheft JATROS Neurologie & Psychiatrie, 2021 Mar. German.
   Google Scholar
• World Health Organization [Internet]. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2019. Geneva (Switzerland): WHO; [cited 2023 Jun 12]. Available from: https://www.whocc.no/atc_ddd_index/
   Google Scholar
• Sousa RD, Gouveia M, Nunes da Silva C, et al. Treatment-resistant depression and major depression with suicide risk – the cost of illness and burden of disease. Front Public Health. 2022;10:898491. doi: 10.3389/fpubh.2022.898491.
   PubMed Web of Science ®Google Scholar
• Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz. Überregionale Auswertung der Dokumentation in landesgesundheitsfondsfinanzierten Krankenanstalten 2019 [Supraregional evaluation of documentation in hospitals financed by state health funds in 2019]. Vienna (Austria): Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz; January 2021. German.
   Google Scholar
• Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz. LKF-Modell 2021 [Austrian DRG model 2021]. Vienna (Austria): Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz; January 2021. German.
   Google Scholar
• Österreichische Gesundheitskasse [Internet]. Gesamtvertrag für Ärzte herunterladen [Download general contract for physicians]. Vienna (Austria): Österreichische Gesundheitskasse (ÖGK); [cited 2021 Jul 15]. Available from: https://www.gesundheitskasse.at/cdscontent/?contentid=10007.879101&portal=oegkvpportal German.
   Google Scholar
• Rechtsinformationssystem des Bundes [Internet]. Verordnung der Wiener Landesregierung über die Festsetzung der Ambulatoriumsbeiträge für die Wiener städtischen Krankenanstalten [Regulation of the Viennese provincial government on the determination of outpatient contributions for the Viennese municipal hospitals]. Vienna (Austria): Bundesministerium für Finanzen; [cited 2021 Jul 15]. Available from: https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=LrW&Gesetzesnummer=20000627&FassungVom=2021-10-04&Artikel=2&Paragraf=&Anlage=&Uebergangsrecht= German.
   Google Scholar
• Walter E, Zehetmayr S. Guidelines zur gesundheitsökonomischen Evaluation Konsenspapier [Guidelines for health-economic evaluations in Austria]. Wien Med Wochenschr. 2006;156(23-24):628–632. German. doi: 10.1007/s10354-006-0360-z.
   PubMedGoogle Scholar
• Statistik Austria. [Internet]. Brutto- und Nettojahreseinkommen nach Altersgruppen 2021 [Gross and net annual income by age group 2021]. Vienna (Austria): Statistik Austria; [cited 2022 Jul 12]. Available from: https://www.statistik.at/fileadmin/pages/333/10_brutto-_und_nettojahreseinkommen_nach_altersgruppen_2021_019351.ods German.
   Google Scholar
• Statistik Austria [Internet]. Abgestimmte Erwerbsstatistik [Adjusted labor force statistics]. Vienna (Austria): Statistik Austria. 2021 [cited 2022 Sep 12]. Available from: https://www.statistik.at/ueber-uns/erhebungen/registerzaehlung/abgestimmte-erwerbsstatistik
   Google Scholar
• World Health Organization. Global burden of disease: concepts and methods: 2004 update. Geneva (Switzerland): WHO; 2008.
   Google Scholar
• Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429–445.
   PubMed Web of Science ®Google Scholar
• Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712–e723. doi: 10.1016/S2214-109X(15)00069-8.
   PubMed Web of Science ®Google Scholar
• IsHak WW, Mirocha J, James D, et al. Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatr Scand. 2015;131(1):51–60. doi: 10.1111/acps.12301.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26(10):2475–2484. doi: 10.1185/03007995.2010.517716.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370–377.
   PubMed Web of Science ®Google Scholar
• Gillain B, Degraeve G, Dreesen T, et al. Real-world treatment patterns, outcomes, resource utilization and costs in treatment-resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium. Pharmacoecon Open. 2022;6(2):293–302. doi: 10.1007/s41669-021-00306-2.
   PubMed Web of Science ®Google Scholar
• Pérez-Sola V, Roca M, Alonso J, et al. Economic impact of treatment-resistant depression: a retrospective observational study. J Affect Disord. 2021;295:578–586. doi: 10.1016/j.jad.2021.08.036.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Drago C, Mandolini D, et al. The costs of treatment resistant depression: evidence from a survey among Italian patients. Expert Rev Pharmacoecon Outcomes Res. 2022;22(3):437–444. doi: 10.1080/14737167.2021.1954507.
   PubMed Web of Science ®Google Scholar
• Conca A, Hinterhuber H, Prapotnik M, et al. Die Elektrokrampftherapie: Theorie und Praxis [Electroconvulsive therapy: theory and practice]. Neuropsychiatrie. 2004;18.1:1–17. German.
   Google Scholar
• Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2021: OECD indicators. Paris (France): OECD Publishing; 2021.
   Google Scholar
• Turnpenny A, Petri G, Finn A, et al. Mapping and understanding exclusion: institutional, coercive and community-based services and practices across Europe. Brussels (Belgium): Mental Health Europe; 2017.
   Google Scholar